SinoMab BioScience Limited (3681.HK)
- Previous Close
1.900 - Open
1.900 - Bid 1.830 x --
- Ask 1.900 x --
- Day's Range
1.830 - 1.900 - 52 Week Range
1.030 - 1.990 - Volume
77,400 - Avg. Volume
201,715 - Market Cap (intraday)
2.074B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.260 - Earnings Date Mar 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. It operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
www.sinomab.comRelated News
Performance Overview: 3681.HK
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3681.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3681.HK
Valuation Measures
Market Cap
2.07B
Enterprise Value
2.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.31k
Price/Book (mrq)
6.49
Enterprise Value/Revenue
1.69k
Enterprise Value/EBITDA
-9.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.46%
Return on Equity (ttm)
-60.39%
Revenue (ttm)
4.39M
Net Income Avi to Common (ttm)
-243.11M
Diluted EPS (ttm)
-0.260
Balance Sheet and Cash Flow
Total Cash (mrq)
234.66M
Total Debt/Equity (mrq)
152.51%
Levered Free Cash Flow (ttm)
-198.61M
Company Insights: 3681.HK
3681.HK does not have Company Insights